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frequency. Five centres performed ELISPOT and multimer 
staining on centrally prepared PBMCs from 3 donors, both 
ex vivo and following IVS. A harmonised IVS protocol 
was designed based on the best-performing protocol(s), 
which was then evaluated in a second phase on 2 donors by 
6 centres. All centres were able to reliably detect antigen-
specific T cells of high/intermediate frequency both ex vivo 
(Phase I) and post-IVS (Phase I and II). The highest fre-
quencies of antigen-specific T cells ex vivo were mirrored 
in the frequencies following IVS and in the detection rates. 
However, antigen-specific T cells of a low/undetectable fre-
quency ex vivo were not reproducibly detected post-IVS. 
Harmonisation of the IVS protocol reduced the inter-labo-
ratory variation observed for ELISPOT and multimer anal-
yses by approximately 20 %. We further demonstrate that 
results from ELISPOT and multimer staining correlated 
after (P < 0.0001 and R2 = 0.5113), but not before IVS. In 
summary, IVS was shown to be a reproducible method that 
benefitted from method harmonisation.
Abstract Ex vivo ELISPOT and multimer staining are 
well-established tests for the assessment of antigen-spe-
cific T cells. Many laboratories are now using a period of 
in vitro stimulation (IVS) to enhance detection. Here, we 
report the findings of a multi-centre panel organised by 
the Association for Cancer Immunotherapy Immunoguid-
ing Program to investigate the impact of IVS protocols on 
the detection of antigen-specific T cells of varying ex vivo 
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Introduction
Accurate assessment of both frequency and functionality of 
T cells to allow reproducible immune monitoring has been 
the focus of many laboratories in a wide range of fields [1–
4]. The methods used for T-cell enumeration, i.e. ELISPOT 
assay and multimer staining, have been the subject of a 
number of harmonisation studies, in particular in the fields 
of infectious diseases [1, 5] and cancer, where large profi-
ciency panels have been conducted both in Europe and the 
United States within the remit of the Association for Can-
cer Immunotherapy Immunoguiding Programme (CIMT-
CIP) [6] and the Cancer Immunotherapy Consortium of 
the Cancer Research Institute (CIC-CRI) [7], respectively. 
Such panels have investigated factors that influence the fre-
quency of responses detected by ex vivo IFNγ ELISPOT 
[6, 8, 9] and multimer staining [10, 11].
More recently laboratories have incorporated a period 
of in vitro stimulation (IVS) prior to assay by ELISPOT or 
multimer staining. Several studies have shown that ex vivo 
IFNγ ELISPOT and cultured ELISPOT measure differ-
ent subsets of effector and memory T cells [12, 13]. Whilst 
the ex vivo ELISPOT quantifies effector cells, the cultured 
ELISPOT can measure T cells of central memory phenotype, 
which are able to proliferate and consequently acquire effec-
tor function [14]. IVS for as little as 1 day, when followed by 
peptide stimulation for 24–48 h in an ELISPOT assay, has 
been shown to enhance cellular responses to M. tuberculo-
sis [4]. We have also shown in a DNA vaccine clinical trial 
in patients with prostate cancer that vaccine peptide-specific 
responses detectable by ELISPOT could be increased by 
33 % following IVS for 9 days prior to assay; 6/30 versus 
16/30 responders for ex vivo and cultured ELISPOT, respec-
tively [15]. Hence, IVS provides an effective method to 
enhance the detection of antigen-specific T-cell populations.
Since laboratories have developed their in-house IVS 
techniques independently, a diverse set of assay parameters 
are in use regarding cell concentration/density, length of 
culture, peptide concentration and type and number of 
exogenous cytokines, among others [16]. An understand-
ing of how comparable and robust individual IVS methods, 
including a correlation of results post-culture with ex vivo 
frequencies, is required to better enable the interpretation 
of data generated following IVS of PBMCs.
Here, we describe our findings from a 2 stage harmoni-
sation process that examined the robustness and variability 
of short-term in vitro culture for the expansion of antigen-
specific T cells of varying ex vivo frequencies. We first 
evaluated the ability of 5 distinct IVS protocols, originat-
ing from 5 laboratories across Europe, to detect pre-defined 
antigen-specific responses in multiple donors by ELISPOT 
assay and multimer staining. Features of the “best-perform-
ing” IVS method(s) were integrated to establish a harmo-
nised protocol that was then used in each centre to further 
evaluate inter-assay (for each centre) and inter-laboratory 
variation in a second phase of the study.
Materials and methods
The following Materials and Methods section is MIATA 
compliant (www.miataproject.org) [17]; further details of 
each centre’s reagents and protocols are provided in Sup-
plementary MIATA Information.
Organisation and panel design
The proficiency panel was conducted in 2 phases with 5 and 
6 centres participating in Phase I and II, respectively, from 
4 European countries (UK, Germany, The Netherlands and 
Switzerland). The panel design is shown in Fig. 1a.
Phase I: Five centres received centrally prepared 
PBMCs from 3 HLA-A2+ donors, peptides (Peptide Syn-
thetics Peptide Protein Research Ltd., Bishops Waltham, 
UK.) and multimers (kindly supplied by the Department 
of Immunology, Institute for Cell Biology, Eberhard-Karls 
University Tübingen) sufficient to perform the requested 
assays. Centres were required to perform (i) ex vivo 
ELISPOT and multimer analysis and (ii) IVS, accord-
ing to the centre’s own established protocol (Fig. 1b and 
Supplementary MIATA Information, IVS Module 2), fol-
lowed by ELISPOT and multimer analysis, for defined 
antigens. IVS was to be performed on 3 occasions, with 
culture set up on different days. Results were reported 
back to the organising centre for analysis. Features of the 
“best-performing” IVS protocol(s) were identified and 
used to establish a harmonised protocol for further testing 
in a second phase.
Phase II: Six centres received centrally prepared 
PBMCs from 2 HLA-A2+ donors, peptides (Peptide 
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Fig. 1  A multi-centre, 2 phase in vitro stimulation proficiency panel 
An overview of the design of the IVS proficiency panel (a). A sche-
matic representation of the 5 IVS protocols used by participating cen-
tres (A–E) in Phase I and the harmonised IVS protocol used by 6 cen-
tres (A–F) in Phase II (b)
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Synthetics Peptide Protein Research Ltd), multimers (pro-
duction in-house), X-Vivo 15 medium (Lonza Group Ltd., 
Basel, Switzerland), l-glutamine (PAA Laboratories Ltd., 
Yeovil, UK.), Pen/Strep (PAA), human AB serum (Lonza 
Group Ltd.) and recombinant IL-2 (R&D Systems Europe 
Ltd., Abingdon, UK.). As for Phase I, centres were required 
to perform harmonised IVS (Fig. 1b) on 3 occasions, each 
followed by ELISPOT and multimer staining. Results were 
reported back to the organising centre for analysis.
Donor PBMC and pre-screening
PBMCs were isolated from anonymised buffy cones (HIV 
status negative) obtained from the National Blood Service, 
Southampton University Hospitals NHS Foundation Trust, 
as previously described [6]. PBMC aliquots were stored in 
liquid nitrogen until shipment on dry ice to participating 
centres, where they were returned to liquid nitrogen until 
required.
Pre-screening of donor PBMCs to ensure consist-
ent viability and recovery upon thawing and to identify 
donors with suitable T-cell reactivity to the HLA-A*0201-
restricted epitope peptides was performed at the organising 
centre. T-cell reactivity to defined viral and tumour-associ-
ated antigens (TAA) (Supplementary Table 1) was deter-
mined by ex vivo and post-IVS IFNγ ELISPOT assay and 
multimer analysis (triplicate). T-cell reactivity was defined 
as high (≥ 100 spot forming cells (SFC)/million), interme-
diate (50–100 SFC/million) or low (21–50 SFC/million) 
using ex vivo ELISPOT data alone; furthermore, responses 
were characterised as low/undetectable if ex vivo ELISPOT 
was ≤ 20 SFC/million, but for which ex vivo multimer 
staining could detect a positive, but low, population of mul-
timer+ T cells. The serology status of the donors to the spe-
cific viral antigens was unknown.
Detection of antigen-specific T-cell responses
Ex vivo (Phase I only) and post-IVS antigen-specific T-cell 
responses were assessed by IFNγ ELISPOT assay and mul-
timer staining; if cell number was limited, cells were priori-
tised for ELISPOT over multimer staining.
IFNγ ELISPOT: For Phase I, a PBMC resting period 
prior to ex vivo ELISPOT was mandated; otherwise, each 
centre performed the ELISPOT assay according to their 
own established protocol (Supplementary MIATA Infor-
mation, ELISPOT Module 2). Recommendations for pep-
tide concentration and cell number were 1 μg/mL (ex vivo 
and post-IVS) and 4 × 105 cells per well (ex vivo, test and 
control wells), respectively. Centres supplied their own 
reagents throughout, with the exception of peptides. Post-
IVS ELISPOT assay set up was more tightly regulated in 
Phase II, with mandatory requirements: (i) all steps of the 
assay to be performed in X-Vivo 15 working medium, (ii) 
plate block in X-Vivo 15 working medium containing 10 % 
AB serum for at least 1 h, (iii) restimulation of cells with 
peptide at 1 μg/mL final concentration and (iv) plating 
of 1 × 104 cells per well (test viral antigens) or 1 × 105 
cells per well (TAA and viral control antigen). All reagents 
required for set up were supplied by the organising centre, 
with the exception of an appropriate wash medium (RPMI 
or equivalent). For both Phase I and II, protocols and rea-
gents required for spot development were the centre’s own.
Multimer Staining: For both Phase I and II, all centres 
used their own established protocol for multimer stain-
ing, with some mandatory requirements: (i) a minimum 
of 1 × 106 (ex vivo) or 0.5 × 106 (post-IVS) cells per test 
were to be stained with all cells to be acquired, (ii) prior 
centrifugation of multimers at 13,000 rpm, 4 °C for 6 min, 
(iii) incubation of cells with multimer at a final concentra-
tion of 5 μg/mL for 30 min at room temperature and (iv) 
surface staining with anti-CD3, anti-CD8, anti-CD4 and 
anti-CD45RA antibodies as a minimum, with the option 
to include additional markers such as a dead cell marker, 
dump channel or other T-cell memory phenotype markers 
(Supplementary MIATA Information, Multimer Module 2). 
Centres supplied their own reagents throughout, with the 
exception of multimers.
Harmonised in vitro stimulation
A harmonised IVS protocol was designed based upon 
features of the “best-performing” protocol(s) from Phase 
I, defined as one which delivered high antigen-specific 
T cells whilst maintaining low background and low 
inter-assay variation. The harmonised IVS protocol was 
then tested by 6 centres in Phase II. In brief, PBMCs 
were thawed, washed and resuspended in X-Vivo 15 
medium (Lonza) supplemented with 1 % l-glutamine 
(200 mM; PAA), 1 % Penicillin/Streptamycin (10,000U/
mL and 10,000mcg/mL; PAA) and 10 % human AB 
serum (Lonza). Cells were counted and volume adjusted 
to 4 × 106 viable cells/mL. One mL of cell suspen-
sion was added to each well of a 24-well, flat-bottomed 
plate, along with 1 mL of X-Vivo 15 working medium 
plus antigenic peptides (Peptide Synthetics Peptide Pro-
tein Research Ltd.) and recombinant IL-2 (R&D Systems 
Europe Ltd.) to give a final concentration of 1 μg/mL 
and 20 IU/mL, respectively, in a final volume of 2 mL. 
Plates were incubated at 37 °C with 5 % CO2. On days 4, 
6, 8 and 11, 1 mL of culture medium was removed from 
each well and replaced with 1 mL of X-Vivo 15 work-
ing medium plus recombinant IL-2 to a final concentra-
tion of 20 IU/mL. On day 13, the cells were harvested, 
washed twice and resuspended into X-Vivo 15 working 
medium. Cells were counted and volume adjusted to 
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1 × 106 viable cells/mL for subsequent ELISPOT assay 
and multimer staining.
Data acquisition
Each centre was required to complete a detailed question-
naire specifying the protocols and reagents used for the 
assays, including details of cell thawing, cell counting and 
QC of material, ex vivo ELISPOT and multimer staining, 
IVS and post-IVS ELISPOT and multimer staining.
Enumeration of IFNγ-producing cells was performed by 
participating centres using a suitable ELISPOT plate reader 
system and software. All raw data (SFC per well) were 
entered into a report form (Microsoft Excel spread sheet 
format) and supplied to the organising centre for central-
ised analysis.
For the analysis of multimer staining, samples were 
acquired by participating centres on a suitable flow cytome-
ter. All raw data (FCS files) were returned to the organising 
centre for centralised gating using FlowJo software (Trees-
tar Inc., Ashland, USA). All centres in Phase I and II, with 
the exception of Centre C, used a Live/Dead discrimination 
dye and therefore samples were firstly gated on a live cell 
population. A lymphocyte gate based on size and granular-
ity followed, before defining CD3+CD4−CD8+multimer+ 
cells. As the donors were known to be HIV seronegative, 
HIV-multimer+ populations were used as a negative control 
and test antigen multimer+ gates were set accordingly.
Data analysis
Centralised analysis of the raw data was performed by the 
organising centre. ELISPOT data were first processed by 
expressing each well as SFC per million PBMCs as per val-
idation of ELISPOT assay [18, 19], followed by subtract-
ing the mean spot number of the triplicate of unstimulated 
cells from that of the test triplicate. A mean and SD were 
calculated for each antigen-specific triplicate. An antigen-
specific response was reported if the mean was both ≥20 
(ex vivo) or ≥500 (post-IVS) SFC per million PBMCs and 
2 SD above the mean of HIV stimulated wells; an informed 
threshold value for positivity above background (SFC/mil-
lion) was applied for ex vivo and post-IVS ELISPOT based 
on previous data from the organising centre.
Multimer+ T cells were expressed as a percentage of the 
total CD3+CD4−CD8+ T cells analysed; a mean and SD 
were calculated for each antigen-specific multimer (from 
3 repeated assays). All dot plots (test and control) were 
examined by 3 independent analysts in a blinded fashion 
and scores were given based upon both the frequency and 
appearance of multimer+ T cells- (2) a clustered popula-
tion, (1) ambiguous population (0) clearly negative. A posi-
tive response was defined as a combined score of ≥5.
Inter-assay (for each centre) and inter-laboratory vari-
ability was calculated using the coefficients of variation 
(CV): % CV = SD/mean × 100. Correlations were evalu-
ated using the Pearson’s correlation coefficient (R) and the 
coefficient of determination (R2), with significance testing 
using Student’s t test and a confidence level of 99 %.
Results
All centres completed the required assays and returned the 
raw data to the organising centre for central analysis, which 
included all replicates unless specifically stated (Supple-
mentary MIATA Information, ELISPOT and Multimer 
Module 4A).
Cell recovery and cell viability
To confirm that each centre was provided with PBMCs of 
comparable quality, cell recovery and cell viability were 
assessed after initial thawing (Supplementary Fig. 1, left 
panels). Cell recovery after thawing varied for each donor 
and for each centre, consistent with a non-standardised 
method of thawing, whilst cell viability was consistently 
high.
Cell recovery (relative to the cell number plated on day 
1) and cell viability were also assessed after IVS (Supple-
mentary Fig. 1, right panels). In Phase I, all participants, 
except Centre A, recovered fewer cells following IVS than 
were plated. No relationship was observed between the 
length of IVS and the cell recovery post-IVS; however, 
the cytokine milieu did affect the number of cells recov-
ered (Supplementary Fig. 2). All 5 centres added IL-2 
to the IVS, with 3 centres (A, B and C) using additional 
cytokines. The IVS protocol used by Centre A required the 
addition of IL-2, IL-15 and T-cell growth factor and dis-
played a significantly superior cell recovery for each of the 
3 donors (mean 147 %, P < 0.0001.); Centres B and C used 
IL-2, IL-4 and IL-7 with a mean recovery of 61 % com-
pared to 31 % for Centres D and E that used IL-2 alone. 
After harmonised IVS, cell recovery and cell viability were 
consistent across all centres (Supplementary Figs. 1 and 2).
Phase I: Detection of antigen-specific T cells by ELISPOT 
and multimer staining, ex vivo compared to post-IVS
Phase I of the panel required that each of 5 participat-
ing centres analysed PBMCs from 3 donors (1–3) for the 
presence of T cells specific for HLA-A*0201-restricted 
epitopes from FLU and CMV, as well as HIV, which served 
as a negative control (Supplementary Table 1). Detection 
was by both ELISPOT and multimer staining, ex vivo and 
post-IVS. Pre-screening of donor PBMCs at the organising 
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centre-identified donors as high (donors 1 and 2) and low 
(donor 3) for FLU-specific T cells, whilst CMV-specific 
responses were low/undetectable in all 3 donors.
All 5 centres detected FLU-specific T cells in each of 
the 3 donors by ex vivo ELISPOT and multimer staining 
(Fig. 2a; Table 1a). Mean FLU-specific responses were 
highest in donor 2 with 180 SFC/million (ELISPOT) and 
0.352 % CD8+FLU-multimer+ T cells (multimer), com-
pared to 132 SFC/million and 0.275 % CD8+FLU-mul-
timer+ and 35 SFC/million and 0.299 % CD8+FLU-mul-
timer+ for donors 1 and 3, respectively. Following IVS, all 
centres could detect FLU-specific T cells in all 3 donors by 
multimer staining, but only 4 centres (A, C-E) by ELISPOT 
(Fig. 2a; Table 1a); Centre B detected FLU+ T cells in 
donors 1 and 2, but not 3. Similar to ex vivo analysis, mean 
FLU-specific responses were greatest in donor 2 with 
18729 SFC/million (ELISPOT) and 31.8 % CD8+FLU-
multimer+ T cells (multimer), compared to 17627 SFC/
million and 26.7 % CD8+FLU-multimer+ and 12865 SFC/
million and 8.0 % CD8+FLU-multimer+ for donors 1 
and 3, respectively. Overall, the detection rate for ex vivo 
multimer staining was 93 % increasing to 98 % post-IVS. 
However, for ELISPOT, this decreased from 91 % ex vivo 
to 86 % post-IVS, attributable to weak responses in donor 
3. The IVS protocol used by Centre D consistently gave 
the best performance with the greatest detection rate, SFC/
Table 1  Detection rates of antigen-specific responses assessed by ELISPOT and multimer staining: (a) Phase I, ex vivo and post-IVS and (b) 
Phase II, post-IVS alone
Antigen-specific response criteria, ELISPOT: ≥20 (ex vivo) or ≥500 (post-IVS) SFC/million PBMC and 2 SD above mean HIV control. Anti-
gen-specific response criteria, multimer: combined visual examination score of dot plots ≥5
ND not detected
a
 Mean FLU-specific T cell detection rate for post-IVS ELISPOT and multimer combined was 100, 78, 94, 100 and 89 % for Centres A, B, C, D 
and E, respectively (donors 1, 2 and 3)
b
 Mean CMV-specific T cell detection rate for post-IVS ELISPOT and multimer combined was 8 %, ND, 17, 22 % and ND for Centres A, B, C, 
D and E, respectively (donors 1, 2 and 3)
c
 Only two sets of data were reported due to technical difficulties with one replicate
d
 Only two FCS files were supplied by the centre for centralised analysis
e
 Mean EBV-specific T cell detection rate for post-IVS ELISPOT and multimer combined was 100, 100, 100, 92, 100 and 100 % for Centres A, 
B, C, D, E and F, respectively (donors 4 and 5)
f
 Mean FLU-specific T cell detection rate for post-IVS ELISPOT and multimer combined was 100, 83, 50, 67, 100 and 92 % for Centres A, B, 
C, D, E and F, respectively (donors 4 and 5)
g
 Mean WT1-specific T cell detection rate for post-IVS multimer combined was 25, 25, 33, 33, 17 and 8 % for Centres A, B, C, D, E and F, 
respectively (donors 4 and 5)
Donors Centre A Centre B Centre C Centre D Centre E Mean (%)
1 2 3 1 2 3 1 2 3 1 2 3 1 2 3 1 2 3
(a)
FLUa ELISPOT Ex vivo 3/3 3/3 3/3 3/3 2/3 1/3 3/3 3/3 3/3 3/3 3/3 2/3 3/3 3/3 3/3 100 93 80 91
Post-IVS 2/2c 2/2c 2/2c 3/3 2/3 0/3 3/3 3/3 2/3 3/3 3/3 3/3 3/3 3/3 2/3 100 93 64 86
Multimer Ex vivo 3/3 3/3 1/3 3/3 3/3 3/3 3/3 3/3 3/3 2/2d 3/3 2/3 2/2c 2/2c 2/2c 100 100 79 93
Post-IVS 2/2c 2/2c 2/2c 3/3 3/3 3/3 3/3 3/3 3/3 3/3 3/3 3/3 3/3 3/3 2/3 100 100 93 98
CMVb ELISPOT Ex vivo 0/3 0/3 0/3 0/3 0/3 0/3 0/3 0/3 0/3 0/3 0/3 0/3 0/3 0/3 0/3 0 0 0 0
Post-IVS 0/2c 1/2c 0/2c 0/3 0/3 0/3 0/3 0/3 0/3 0/3 0/3 0/3 0/3 0/3 0/3 0 7 0 2
Multimer Ex vivo 0/3 2/3 0/3 0/3 0/3 0/3 1/3 0/3 0/3 0/3 2/3 0/3 0/2c 0/2c 0/2c 7 29 0 12
Post-IVS 0/2c 0/2c 0/2c 0/3 0/3 0/3 0/3 1/3 2/3 1/3 2/3 1/3 0/3 0/3 0/3 7 20 20 17
Donors Centre A Centre B Centre C Centre D Centre E Centre F Mean (%)
4 5 4 5 4 5 4 5 4 5 4 5 4 5
(b)
EBVe ELISPOT 3/3 3/3 3/3 3/3 3/3 3/3 3/3 2/3 3/3 3/3 3/3 3/3 100 94 97
Multimer 3/3 3/3 2/2d 3/3 3/3 3/3 3/3 3/3 3/3 3/3 3/3 3/3 100 100 100
FLUf ELISPOT 3/3 3/3 2/3 2/3 0/3 0/3 1/3 1/3 3/3 3/3 3/3 2/3 67 61 64
Multimer 3/3 3/3 3/3 3/3 3/3 3/3 3/3 3/3 3/3 3/3 3/3 3/3 100 100 100
WT1 g ELISPOT 0/3 0/3 0/3 0/3 0/3 0/3 0/3 0/3 0/3 0/3 0/3 0/3 0 0 0
Multimer 1/3 2/3 1/3 2/3 2/3 2/3 2/3 2/3 0/3 2/3 0/3 1/3 33 61 47
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million count and % CD8+FLU-multimer+ T cells, indica-
tive of a robust IVS protocol.
Three centres (A, C and D) detected CMV-specific 
responses in 1/3 donors by ex vivo multimer staining, with a 
mean of all positive responses of 0.776 % CD8+CMV-mul-
timer+ T cells (Fig. 2b); a mean detection rate of 7 and 29 % 
was observed for donors 1 and 2, respectively (Table 1a). In 
contrast, ex vivo ELISPOT did not reveal CMV-specific T 
cells. Following IVS, Centres C and D continued to detect 
CMV+ T cells by multimer staining in up to 3 donors (mean 
0.104 % CD8+CMV-multimer+); a mean detection rate of 
7, 20 and 20 % was observed for donors 1, 2 and 3, respec-
tively (Fig. 2b; Table 1a). Only Centre A detected CMV+ 
T cells by post-IVS ELISPOT, which was observed only 
in donor 2 in 1/2 replicates. Overall, the combined CMV 
detection rate was 6 % ex vivo and 10 % post-IVS.
No T-cell responses to HIV reached the threshold for 
a positive response based on the pre-define criteria (see 
‘Materials and Methods, Data analysis’ and Supplemen-
tary MIATA Information, ELISPOT and Multimer Module 
4B) and were thus deemed negligible (Fig. 2c), consistent 
with these blood donors being HIV negative.
Example raw data and mean SFC/million and % mul-
timer+ T cells are shown in Supplementary MIATA Infor-
mation, ELISPOT and Multimer Module 3B.
Amplification of antigen-specific T-cell responses post-IVS
Amplification of FLU-specific T cells following IVS ver-
sus ex vivo assay was assessed in Phase I (Supplementary 
Table 2). The magnitude of T-cell amplification was highly 
variable depending on the donor PBMCs, IVS protocol and 
means of detection. In general, amplification was greatest 
when detection was via ELISPOT, with an overall mean 
fold increase of 185.1 ± 238.5 (ELISPOT) compared to 
98.1 ± 142.9 (multimer).
Background IFNγ production in ELISPOT, ex vivo 
and post-IVS
The impact of IVS on the background level of IFNγ pro-
duction detected in ELISPOT was assessed by comparing 
the mean SFC/million count of unstimulated cells detected 
ex vivo with that post-IVS for each of 5 centres in Phase I 
(example raw data shown in Supplementary MIATA Infor-
mation, ELISPOT Module 3B). Background IFNγ produc-
tion increased following IVS for all centres; mean 9, 7 and 
4 SFC/million ex vivo compared to 86, 254 and 135 SFC/
million (mean from centres B-E only) post-IVS for donors 
1, 2 and 3, respectively. Centre A displayed very high 
background IFNγ production following IVS; 1489, 2156 
and 6711 SFC/million for donors 1, 2 and 3, respectively. 
A resting phase (~ 24 h) after IVS and prior to ELISPOT 
plate set up was included by Centre E; however, this did not 
appear to reduce background IFNγ production.
Development of a harmonised IVS protocol
A harmonised IVS protocol was designed to incorpo-
rate features from the “best-performing” protocol(s) from 
Phase I, in order to produce a method capable of delivering 
high amplification of antigen-specific T cells with a maxi-
mum detection rate whilst displaying limited inter-assay 
variability. The IVS protocol used by Centre D resulted in 
Table 2  Summary of mean inter-assay and inter-laboratory % coefficients of variation for Phase I and Phase II: (a) high/intermediate/low 
response and (b) low/undetectable response
N/A not applicable
ELISPOT: %CV Multimer: %CV
Inter-assay Inter-laboratory Inter-assay Inter-laboratory
(a)
Phase I Ex vivo FLU 40.6 66.9 33.3 83.2
Phase I Post-IVS FLU 48.7 84.6 51.5 84.6
Phase II EBV/FLU 55.9 70.6 48.5 58.5
Mean 48.4 ± 7.7 44.4 ± 9.8 %
ELISPOT: %CV Multimer: %CV
Inter-assay Inter-laboratory Inter-assay Inter-laboratory
(b)
Phase I Ex vivo CMV 126.0 163.2 49.1 115.0
Phase I Post-IVS CMV 127.9 217.2 76.1 239.8
Phase II WT1 N/A N/A 51.2 113.3
Mean 127.0 ± 1.3 58.8 ± 15.0 %
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100 % detection rate of FLU-specific T cells (ELISPOT 
and multimer) and generated the greatest FLU-specific 
T-cell responses (mean 26615 SFC/million and 42.6 % 
CD8+FLU-multimer+ T cells). Moreover, it displayed 
the largest (ELISPOT) and third largest (multimer) fold 
increase in FLU-specific T cells compared to ex vivo and 
the lowest inter-assay variation for multimer (see ‘Phase 
I/II: Inter-assay and inter-laboratory variation’; not evalu-
able for ELISPOT), whilst maintaining a low background. 
Therefore, the harmonised protocol designed (see ‘Mate-
rials and Methods, Harmonised in vitro stimulation’) was 
most similar to that used by Centre D; however, some 
modifications to the protocol were incorporated for ease of 
multi-centre application.
Phase II: Detection of antigen-specific T cells by ELISPOT 
and multimer staining post-harmonised IVS
Phase II of the panel required that each of 6 participating 
centres analyse PBMCs from 2 donors (4–5) for the pres-
ence of CD8+ T cells specific for HLA-A*0201-restricted 
epitopes from FLU, EBV and the TAA Wilm’s tumour anti-
gen 1 (WT1), as well as HIV, which served as a negative 
control (Supplementary Table 1). Detection was by both 
ELISPOT and multimer staining following harmonised 
IVS. Pre-screening of donor PBMCs at the organising 
centre-identified donors as high (donor 4) and intermediate 
(donor 5) for EBV-specific T cells, low (donors 4 and 5) for 
FLU-specific T cells and low/undetectable (donor 5 alone) 
for WT1-specific T cells.
All 6 centres detected EBV-specific T cells in both 
donors by post-IVS ELISPOT and multimer stain-
ing (Fig. 3a); a mean detection rate of 100 and 94 % by 
ELISPOT and 100 and 100 % by multimer staining was 
observed for donors 4 and 5, respectively (Table 1b). Mean 
EBV-specific responses were greatest in donor 4 with 
18813 SFC/million (ELISPOT) and 48.8 % CD8+EBV-
multimer+ T cells (multimer), compared to 7445 SFC/
million and 22.1 % CD8+EBV-multimer+ for donor 5. 
Overall, a combined detection rate of 97 and 100 % was 
observed for ELISPOT and multimer staining, respectively.
All 6 centres could detect FLU-specific T cells in both 
donors by post-IVS multimer staining, but only 5 centres 
(A, C–F) by ELISPOT (Fig. 3b); Centre C did not detect 
FLU+ T cells in either donor by ELISPOT. The mean 
detection rate was 67 and 61 % by ELISPOT and 100 and 
100 % by multimer staining for donors 4 and 5, respec-
tively (Table 1b). Mean FLU-specific responses were 
greatest in donor 5 with 2461 SFC/million (ELISPOT) and 
3.0 % CD8+FLU-multimer+ T cells (multimer), compared 
to 1314 SFC/million and 1.0 % CD8+FLU-multimer+ 
for donor 4. Overall, a combined detection rate of 64 and 
100 % was observed for ELISPOT and multimer staining, 
respectively.
All 6 centres could detect low levels of WT1-specific 
T cells in one or both donors by post-IVS multimer stain-
ing (Fig. 3c); a mean detection rate of 33 and 61 % was 
observed for donors 4 and 5, respectively (Table 1b). Mean 
WT1-specific responses were greatest in donor 5 with 
0.12 % CD8+WT1-multimer+ T cells compared to 0.04 % 
for donor 4. In contrast, no centre was able to detect WT1-
specific T cells by post-IVS ELISPOT.
No T-cell responses to HIV reached the threshold for 
a positive response based on the pre-define criteria (see 
‘Materials and Methods, Data analysis’ and Supplemen-
tary MIATA Information, ELISPOT and Multimer Module 
4B) and were thus deemed negligible (Fig. 3d), consistent 
with these blood donors being HIV negative.
Example raw data and mean SFC/million and % mul-
timer+ T cells are shown in Supplementary MIATA Infor-
mation, ELISPOT and Multimer Module 3B.
Background IFNγ production in ELISPOT 
post-harmonised IVS
The mean background IFNγ production after harmonised 
IVS in Phase II was comparable to that observed in Phase 
I; 341 and 65 SFC/million for donors 4 and 5, respectively 
(example raw data is shown in Supplementary MIATA 
Information, ELISPOT Module 3B).
Phase I/II: Inter-assay and inter-laboratory variation
Inter-assay (for each centre) and inter-laboratory %CVs 
were calculated for Phase I and II data, as summarised 
in Table 2. The inter-assay variation of ELISPOT and 
multimer assays remained consistent whether measured 
ex vivo or post-IVS as would be predicted based on the 
execution of replicates by a common operator (Table 2; 
Fig. 2  Antigen-specific T-cell responses observed ex vivo and post-
IVS in Phase I The responses of 3 donors (1–3) to the viral antigens 
FLU (a), CMV (b) and HIV (c) were assessed by IFNγ ELISPOT 
assay and multimer staining, both ex vivo and post-IVS. The criteria 
for a positive response for ELISPOT and multimer are as described 
in the Materials and Methods and Supplementary MIATA Informa-
tion, ELISPOT and Multimer Module 4B. Triplicates are shown for 
each centre except Centres A and E for which only two sets data 
were reported due to technical difficulties with one replicate; Centre 
A, post-IVS ELISPOT and multimer staining replicate 1; Centre E, 
ex vivo multimer staining replicate 3. Centre A, blue; Centre B, red; 
Centre C, green; Centre D, orange; Centre E, pink. Grey dashed line 
denotes the threshold for a positive response in ex vivo ELISPOT (20 
SFC/million); black dashed line denotes the threshold for a positive 
response in post-IVS ELISPOT (500 SFC/million). For Centre D 
post-IVS ELISPOT (donor 1–3, replicate 1–3) test wells were satu-
rated with SFC too numerous to count, therefore, these wells were 
reported with a maximum spot number of 2000. ND, not detected
◂
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for a breakdown of the inter-assay %CV for individual 
centres see Supplementary Tables 3 and 4). A lower level 
of inter-assay variation was observed for responses that 
were robustly detected (high/intermediate/low response) 
compared to low/undetectable responses; mean combined 
inter-assay %CV was 48.4 ± 7.7 % and 44.4 ± 9.8 % 
(high/intermediate/low response) and 127.0 ± 1.3 and 
58.8 ± 15.0 % (low/undetectable response) for ELIS-
POT and multimer staining, respectively. In Phase I, IVS 
of PBMCs prior to assay by ELISPOT and, to a lesser 
extent multimer staining, resulted in an increase in the 
mean inter-laboratory %CV compared to ex vivo assay 
(Table 2 and Supplementary Table 5); an increase by 17.7 
and 1.4 % (high/intermediate/low response) and 54.0 
and 124.8 % (low/undetectable response) for ELISPOT 
and multimer staining, respectively. In Phase II, which 
used a harmonised IVS protocol that included the use of 
centrally prepared reagents, the mean inter-laboratory 
%CV was reduced (Table 2 and Supplementary Table 6). 
For robust responses (high/intermediate/low response), 
inter-laboratory %CV decreased by 14.0 and 26.1 % for 
ELISPOT and multimer staining, respectively, whilst for 
low/undetectable responses a decrease of 126.5 % was 
observed for multimer staining; inter-laboratory %CV 
could be calculated for ELISPOT since no responses 
were detected.
Fig. 3  Antigen-specific T-cell responses observed post-harmonised 
IVS in Phase II The responses of 2 donors (4 and 5) to the viral and 
tumour-associated antigens EBV (a), FLU (b), WT1 (c) and HIV (d) 
were assessed by IFNγ ELISPOT assay and multimer staining post-
harmonised IVS; ex vivo data (mean of triplicate) generated by the 
organising centre during pre-screening are also shown. The criteria 
for a positive response for ELISPOT and multimer staining are as 
described in the Materials and Methods and Supplementary MIATA 
Information, ELISPOT and Multimer Module 4B. Triplicates are 
shown for each centre except Centre B (post-IVS multimer staining 
donor 4) for which only two FCS files were supplied to the organis-
ing centre for central analysis. Centre A, blue; Centre B, red; Centre 
C, green; Centre D, orange; Centre E, pink; Centre F, purple. Grey 
dashed line denotes the threshold for a positive response in ex vivo 
ELISPOT (20 SFC/million); black dashed line denotes the threshold 
for a positive response in post-IVS ELISPOT (500 SFC/million). ND, 
not detected
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Phase I/II: Correlation of ex vivo, post-IVS, ELISPOT 
and multimer responses
Phase I ex vivo and post-IVS responses detected by both 
ELISPOT and multimer staining were evaluated for the 
existence of any correlation using R2 and significance test-
ing at 99 % confidence (Fig. 4 and Supplementary Table 7). 
Overall, a significant (P < 0.0001) positive correlation was 
observed between ex vivo ELISPOT and post-IVS ELIS-
POT, but was associated with a weak R2 value of 0.3312 
(Fig. 4a). Upon dissection and examination at the level of 
individual donors, significance of this correlation was only 
maintained for donor 2 (R2 = 0.5411 and P = 0.0027). 
There was no correlation observed between ex vivo mul-
timer and post-IVS multimer or between ex vivo ELISPOT 
and ex vivo multimer (Fig. 4b, c). Examination of Phase I 
and II post-IVS ELISPOT and multimer responses revealed 
a significant (P < 0.0001) positive correlation with an R2 
value of 0.5113 (Fig. 4d).
Discussion
Data generated from this multi-centre exploratory panel 
have enabled a better understanding of the impact of IVS 
on the detection of antigen-specific T cells, including an 
insight into performance characteristics of different IVS 
protocols. In Phase I, we compared 5 different IVS tech-
niques, and despite the large number of variables between 
protocols, all centres were able to expand and detect anti-
gen-specific T cells above a pre-defined criteria for posi-
tivity. FLU-specific T cells were found in all three donors, 
but at varying frequencies. The two donors that displayed 
the highest frequencies ex vivo also had the highest fre-
quencies following IVS, and in parallel the greatest detec-
tion rate (often 100 %). The third donor displayed a lower 
frequency of FLU-specific T cells and this corresponded 
to a reduced rate of detection, both for ex vivo and post-
IVS assay. This was more pronounced for ELISPOT where 
‘missed’ responses were in the main due to the number of 
IFNγ SFC falling short of 2 SD above background (HIV 
stimulated wells), and thus failing to achieve the criteria 
for a positive response. We had made recommendations 
to participating centres on the number of cells per well to 
plate following IVS based on our own experience of the 
responses generated by these donors during pre-screening 
assays. In hindsight, this recommendation was not optimal 
since the degree of T-cell expansion achieved by each of 
the different IVS protocols varied greatly. For some cen-
tres, T-cell expansion after IVS was lower and, therefore, 
the detection of an antigen-specific T-cell response may 
have benefitted from plating more cells during assay set 
up. In situations where the presence and level of reactivities 
are unknown, it may also be beneficial to plate cells at two 
concentrations to increase accurate enumeration of the anti-
gen-specific T-cell frequency. We identified this also as the 
cause for responses missed by multimer staining, where too 
few CD8+ T cells were acquired (below 100,000 events). 
This factor has already been identified and reported as key 
for detecting antigen-specific T cells by multimer [10, 11].
A harmonised IVS protocol was designed based on 
the data from Phase I for further testing. Both donors 
investigated in Phase II had high/intermediate frequen-
cies for EBV- and low for FLU-specific T cells ex vivo 
Fig. 4  Correlation of ex vivo 
and post-IVS and ELISPOT and 
multimer responses in Phase 
I and II The responses of all 
donors (1–5), where appropri-
ate, were assessed for the exist-
ence of significant (<0.01 %) 
correlation: Phase I, ex vivo 
ELISPOT with post-IVS ELIS-
POT (a); ex vivo multimer with 
post-IVS multimer (b); ex vivo 
ELISPOT with ex vivo mul-
timer (c); Phase I and II, post-
IVS ELISPOT with post-IVS 
multimer (d). Correlations were 
evaluated using the Pearson’s 
correlation coefficient (R) and 
the coefficient of determination 
(R2), as shown on the bottom 
right of each graph. Significance 
testing used the Student’s t test 
and a confidence level of 99 %
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(pre-screening), and these were expanded well and reliably 
across all 6 centres using the harmonised IVS protocol. 
High detection rates were achieved, with consistent 100 % 
detection by multimer staining. As with Phase I, positive 
responses ‘missed’ by ELISPOT were associated with a 
lower frequency of antigen-specific T cells (FLU), which 
may be attributed to plating too few cells at set up. Overall, 
the higher the ex vivo frequency of the response the less 
variability in expansion was observed across the centres. As 
expected, the use of the harmonised IVS protocol reduced 
inter-laboratory variation.
Examination of the T-cell reactivities of our donors by 
both ELISPOT and multimer staining has enabled us to 
interpret the ex vivo and post-IVS assays with more clar-
ity. In Phase I, FLU-specific T cell responses detected by 
ELISPOT ex vivo compared to post-IVS showed a cor-
relation (P < 0.0001), but with a low R2 value. Further-
more, when these responses were dissected and examined 
for individual donors, significance in this correlation was 
maintained for only 1/3 donors tested. The correlation was 
therefore donor dependent and must be a reflection of the 
phenotype of the cells present in vivo at the time samples 
were taken. Other studies in HIV [13], EBV [20], Hepatitis 
C [21] and malaria [22] have found that there is no corre-
lation between ex vivo and cultured ELISPOT when com-
paring T-cell frequencies to the same antigen. These stud-
ies compared groups of donors and did not dissect the data 
at the level of the individual. Furthermore, our data show 
that ex vivo ELISPOT and multimer did not correlate and 
illustrate that these assays measure different T-cell popula-
tions within a heterogeneous population of antigen-specific 
T cells.
However, post-IVS, our data from Phase I and II com-
bined demonstrated that a significant correlation became 
visible between T cell responses detected by ELISPOT and 
multimer staining (P < 0.0001 and R2 = 0.5113). A likely 
explanation is that antigen-specific memory T cells pro-
liferate and acquire an effector phenotype that can readily 
produce IFNγ for detection by both ELISPOT and mul-
timer staining during IVS [23]. This is also supported by 
a study by Todryk et al. [12] that showed diminished IFNγ 
antigen-specific T-cell responses post-IVS when central 
memory cells are depleted pre-culture.
An important aspect of this study concerned the con-
fidence by which a low level, borderline response can be 
affirmed to be a true positive or a true negative, a common 
quandary when testing for T-cell reactivities of unknown 
but anticipated low magnitude in immunotherapy clinical 
trials. In the past, we have unambiguously detected PSMA-
specific T cells in vaccinated patients following, but not 
before, IVS by ELISPOT, suggesting that IVS can indeed 
be a useful tool for revealing reactivities that are undetect-
able or ambiguous ex vivo [15, 24]. However, in this study, 
the ambiguous CMV and WT1 responses were not resolved 
either ex vivo or following IVS despite a large number of 
assays performed within as well as across centres and by 
two methods. An increase in the number of assay replicates 
is generally beneficial in confirming a result; however, 
where there is inconsistency, as in this study, the decision 
making process is not helped. With limited patient sam-
ples available in trials, a large number of assay repeats may 
further not be feasible. In these cases, a complementary 
assay to confirm the presence or absence of antigen-spe-
cific response may instead be a viable alternative to assay 
repeats.
However, care must be taken not to disregard a positive 
response should the result from multiple assays be conflict-
ing, particularly if the assays measure different T cell quali-
ties such as structural presence of an antigen-specific TCR 
(multimer) as opposed to a functional ability of antigen-
specific T cells (ELISPOT). There are two extra considera-
tions that may lend weight to a clear response in the mul-
timer assay. In contrast to the ELISPOT, the number of cells 
evaluated can be increased during the experiment, limited 
only by the total number of cells available. Therefore, the 
ability to detect low frequency T-cell responses ex vivo may 
be improved by multimer analysis over ELISPOT. Addition-
ally, multimer staining captures T cells independently of the 
cell’s functional characteristics and is not influenced by the 
presence of immunosuppressive cells that may also circulate 
in patients and that will also be included in the test assay.
Our overall conclusion is that IVS can be a robust and 
reproducible tool that can be applied even in the multi-cen-
tre setting. A several log fold expansion of cells is achiev-
able and that opens extra opportunity for further study, 
for example, for TCR rescue and cloning. Clearly IVS is 
not the final solution in every case to resolve the ambigu-
ity of a borderline T-cell reactivity measured ex vivo as we 
demonstrate here. The most robust discrimination appears 
to result from a combination of a structural and functional 
evaluation in parallel. This is the approach we are taking 
for our future studies by building sample collection in a 
way that takes this into account.
Acknowledgments This study and the CIP proficiency panel pro-
gramme are supported by the Wallace Coulter Foundation (Florida, 
USA). Work in Southampton was supported by the Experimental 
Cancer Medicine Centre (ECMC) initiative jointly funded by Cancer 
Research UK and the Departments of Health for England, Scotland, 
Northern Ireland and Wales. Cecile Gouttefangeas and Karoline Laske 
are supported by a grant from Deutsche Forschungsgemeinschaft SFB 
685/Z5. We thank Sonja Heidu for production of multimers (Phase I) 
and excellent technical assistance. We thank Leon Douglas for produc-
tion of multimers (Phase II). We thank Kathy Tier for technical sup-
port. The manuscript does not contain clinical studies or patient data.
Conflict of interest The authors declare that they have no conflict 
of interest.
1211Cancer Immunol Immunother (2014) 63:1199–1211 
1 3
Open Access This article is distributed under the terms of the Crea-
tive Commons Attribution License which permits any use, distribu-
tion, and reproduction in any medium, provided the original author(s) 
and the source are credited.
References
 1. Boaz MJ, Hayes P, Tarragona T, Seamons L, Cooper A, Birungi 
J, Kitandwe P, Semaganda A, Kaleebu P, Stevens G, Anzala O, 
Farah B, Ogola S, Indangasi J, Mhlanga P, Van Eeden M, Tha-
kar M, Pujari A, Mishra S, Goonetilleke N, Moore S, Mahmoud 
A, Sathyamoorthy P, Mahalingam J, Narayanan PR, Ramanathan 
VD, Cox JH, Dally L, Gill DK, Gilmour J (2009) Concordant 
proficiency in measurement of T-cell immunity in human immu-
nodeficiency virus vaccine clinical trials by peripheral blood 
mononuclear cell and enzyme-linked immunospot assays in labo-
ratories from three continents. Clin Vaccine Immunol 16:147–155
 2. Schloot NC, Meierhoff G, Karlsson Faresjö M, Ott P, Putnam 
A, Lehmann P, Gottlieb P, Roep BO, Peakman M, Tree T (2003) 
Comparison of cytokine ELISpot assay formats for the detection of 
islet antigen autoreactive T cells. Report of the third immunology 
of diabetes society T-cell workshop. J Autoimmun 21:365–376
 3. Scheibenbogen C, Romero P, Rivoltini L, Herr W, Schmittel 
A, Cerottini JC, Woelfel T, Eggermont AM, Keilholz U (2000) 
Quantitation of antigen-reactive T cells in peripheral blood by 
IFNgamma-ELISPOT assay and chromium-release assay: a four-
centre comparative trial. J Immunol Methods 244:81–89
 4. Smith SG, Joosten SA, Verscheure V, Pathan AA, McShane H, Otten-
hoff TH, Dockrell HM, Mascart F (2009) Identification of major 
factors influencing ELISpot-based monitoring of cellular responses 
to antigens from Mycobacterium tuberculosis. PLoS ONE 4:e7972
 5. Cox, J. H., Ferrari, G., Kalams, S. A., Lopaczynski, W., Oden, N., 
D’souza, M. P., Group, E. C. S (2005) Results of an ELISPOT 
proficiency panel conducted in 11 laboratories participating in 
international human immunodeficiency virus type 1 vaccine tri-
als. AIDS Res Hum Retroviruses 21:68–81
 6. Mander A, Gouttefangeas C, Ottensmeier C, Welters MJ, Low L, 
van der Burg SH, Britten CM (2010) Serum is not required for 
ex vivo IFN-gamma ELISPOT: a collaborative study of different 
protocols from the European CIMT Immunoguiding Program. 
Cancer Immunol Immunother 59:619–627
 7. Janetzki S, Panageas KS, Ben-Porat L, Boyer J, Britten CM, Clay 
TM, Kalos M, Maecker HT, Romero P, Yuan J, Kast WM, Hoos 
A (2008) Results and harmonization guidelines from two large-
scale international Elispot proficiency panels conducted by the 
Cancer Vaccine Consortium (CVC/SVI). Cancer Immunol Immu-
nother 57:303–315
 8. Filbert H, Attig S, Bidmon N, Renard BY, Janetzki S, Sahin U, Wel-
ters MJ, Ottensmeier C, van der Burg SH, Gouttefangeas C, Britten 
CM (2013) Serum-free freezing media support high cell quality and 
excellent ELISPOT assay performance across a wide variety of dif-
ferent assay protocols. Cancer Immunol Immunother 62:615–627
 9. Janetzki S, Price L, Britten CM, van der Burg SH, Caterini J, 
Currier JR, Ferrari G, Gouttefangeas C, Hayes P, Kaempgen E, 
Lennerz V, Nihlmark K, Souza V, Hoos A (2010) Performance 
of serum-supplemented and serum-free media in IFNgamma 
Elispot Assays for human T cells. Cancer Immunol Immunother 
59:609–618
 10. Britten CM, Janetzki S, Ben-Porat L, Clay TM, Kalos M, Mae-
cker H, Odunsi K, Pride M, Old L, Hoos A, Romero P (2009) 
Harmonization guidelines for HLA-peptide multimer assays 
derived from results of a large scale international proficiency 
panel of the Cancer Vaccine Consortium. Cancer Immunol 
Immunother 58:1701–1713
 11. Britten CM, Gouttefangeas C, Welters MJ, Pawelec G, Koch S, 
Ottensmeier C, Mander A, Walter S, Paschen A, Muller-Berghaus 
J, Haas I, Mackensen A, Kollgaard T, Thor Straten P, Schmitt M, 
Giannopoulos K, Maier R, Veelken H, Bertinetti C, Konur A, Huber 
C, Stevanovic S, Wolfel T, van der Burg SH (2008) The CIMT-mon-
itoring panel: a two-step approach to harmonize the enumeration of 
antigen-specific CD8 + T lymphocytes by structural and functional 
assays. Cancer Immunol Immunother 57:289–302
 12. Todryk SM, Pathan AA, Keating S, Porter DW, Berthoud T, 
Thompson F, Klenerman P, Hill AV (2009) The relationship 
between human effector and memory T cells measured by ex 
vivo and cultured ELISPOT following recent and distal priming. 
Immunology 128:83–91
 13. Calarota SA, Foli A, Maserati R, Baldanti F, Paolucci S, Young 
MA, Tsoukas CM, Lisziewicz J, Lori F (2008) HIV-1-specific T 
cell precursors with high proliferative capacity correlate with low 
viremia and high CD4 counts in untreated individuals. J Immunol 
180:5907–5915
 14. Wherry EJ, Teichgräber V, Becker TC, Masopust D, Kaech SM, 
Antia R, von Andrian UH, Ahmed R (2003) Lineage relation-
ship and protective immunity of memory CD8 T cell subsets. Nat 
Immunol 4:225–234
 15. Chudley L, McCann K, Mander A, Tjelle T, Campos-Perez J, 
Godeseth R, Creak A, Dobbyn J, Johnson B, Bass P, Heath C, Kerr 
P, Mathiesen I, Dearnaley D, Stevenson F, Ottensmeier C (2012) 
DNA fusion-gene vaccination in patients with prostate cancer 
induces high-frequency CD8(+) T-cell responses and increases 
PSA doubling time. Cancer Immunol Immunother 61:2161–2170
 16. Calarota SA, Baldanti F (2013) Enumeration and Characteriza-
tion of Human Memory T Cells by Enzyme-Linked Immunospot 
Assays. Clin Dev Immunol 2013:637649
 17. Janetzki S, Britten CM, Kalos M, Levitsky HI, Maecker HT, 
Melief CJ, Old LJ, Romero P, Hoos A, Davis MM (2009) 
“MIATA”-minimal information about T cell assays. Immunity 
31:527–528
 18. Mander A, Chowdhury F, Low L, Ottensmeier CH (2009) Fit for 
purpose? A case study: validation of immunological endpoint 
assays for the detection of cellular and humoral responses to 
anti-tumour DNA fusion vaccines. Cancer Immunol Immunother 
58:789–800
 19. Russell ND, Hudgens MG, Ha R, Havenar-Daughton C, McEl-
rath MJ (2003) Moving to human immunodeficiency virus type 1 
vaccine efficacy trials: defining T cell responses as potential cor-
relates of immunity. J Infect Dis 187:226–242
 20. Calarota SA, Chiesa A, Zelini P, Comolli G, Minoli L, Bal-
danti F (2013) Detection of Epstein-Barr virus-specific memory 
CD4 + T cells using a peptide-based cultured enzyme-linked 
immunospot assay. Immunology 139:533–544
 21. Godkin AJ, Thomas HC, Openshaw PJ (2002) Evolution of 
epitope-specific memory CD4(+) T cells after clearance of hepa-
titis C virus. J Immunol 169:2210–2214
 22. Pinder M, Reece WH, Plebanski M, Akinwunmi P, Flanagan 
KL, Lee EA, Doherty T, Milligan P, Jaye A, Tornieporth N, Bal-
lou R, McAdam KP, Cohen J, Hill AV (2004) Cellular immunity 
induced by the recombinant Plasmodium falciparum malaria vac-
cine, RTS, S/AS02, in semi-immune adults in The Gambia. Clin 
Exp Immunol 135:286–293
 23. Restifo NP, Dudley ME, Rosenberg SA (2012) Adoptive immu-
notherapy for cancer: harnessing the T cell response. Nat Rev 
Immunol 12:269–281
 24. Widenmeyer M, Griesemann H, Stevanovic´ S, Feyerabend S, 
Klein R, Attig S, Hennenlotter J, Wernet D, Kuprash DV, Sazykin 
AY, Pascolo S, Stenzl A, Gouttefangeas C, Rammensee HG 
(2012) Promiscuous survivin peptide induces robust CD4+ T-cell 
responses in the majority of vaccinated cancer patients. Int J Can-
cer 131:140–149
